Browsing Tag
CryoStor
1 post
Wall Street welcomes Repligen’s $1.5bn BioLife deal, but integration now matters
Repligen’s $1.5bn BioLife deal targets recurring cell therapy revenue. See why investors welcomed the bet and where execution risk remains.